| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/13/2006 | EP1729727A2 Imroved formulations of 6-mercaptopurine |
| 12/13/2006 | EP1729724A1 Inhalent formulation containing sulfoalkyl ether gamma-cyclodextryn and corticosteroid |
| 12/13/2006 | EP1729719A1 Composition comprising sodium silicate for use in the treatment of dry skin conditions |
| 12/13/2006 | EP1729598A1 Composition; use of a composition and a method for treating obesity |
| 12/13/2006 | EP1729597A1 The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome |
| 12/13/2006 | EP1664055B1 9-amino-podophyllotoxin derivatives, method for the production thereof and pharmaceutical compositions containing said derivatives |
| 12/13/2006 | EP1596856B1 Drugs containing substituted 2-aryl-aminoacetic acid compounds and/or substituted 2-heteroaryl-aminoacetic acid compounds |
| 12/13/2006 | EP1482975B1 Prevention of tissue adhesion |
| 12/13/2006 | EP1478382B1 Method for producing a powder inhalant containing a salt of the cgrp antagonist bibn4096 |
| 12/13/2006 | EP1478372B1 Long acting parasiticidal composition containing a salicylanilide compound, a polymeric species and at least one other anti-parasitic compound |
| 12/13/2006 | EP1446127B1 Triazepine derivatives as neurotrophic agents |
| 12/13/2006 | EP1440079B1 Acyclic linker-containing oligonucleotides and uses thereof |
| 12/13/2006 | EP1436877B1 An intelligent serial battery charger and charging block |
| 12/13/2006 | EP1427424A4 Lpa receptor agonists and antagonists and methods of use |
| 12/13/2006 | EP1425014B1 Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators |
| 12/13/2006 | EP1420788B1 Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders |
| 12/13/2006 | EP1404853B1 Process for the production of allicin |
| 12/13/2006 | EP1397132A4 Pirenzepine ophthalmic gel |
| 12/13/2006 | EP1392676B1 Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands |
| 12/13/2006 | EP1385823B1 Guanidino compounds as melanocortin-4 receptor (mc4-r) agonists |
| 12/13/2006 | EP1383765B1 Carboline derivatives as inhibitors of phosphodiesterase 5 (PDE5) for the treatment of cardiovascular diseases and erectile dysfunction |
| 12/13/2006 | EP1372737B8 Preparation for the prophylaxis of restenosis |
| 12/13/2006 | EP1333838B1 Compounds comprising a phytosterol and/or phytostanol moiety and ascorbic acid and use thereof as weight regulating agents |
| 12/13/2006 | EP1328252B1 Transdermal pharmaceutical delivery composition |
| 12/13/2006 | EP1326599B1 Use of aivlosin for treating or preventing Lawsonia infections in pigs. |
| 12/13/2006 | EP1313488B1 Compositions and methods for improving cardiovascular function |
| 12/13/2006 | EP1287133B1 Regulation of human dopamine-like g protein-coupled receptor |
| 12/13/2006 | EP1272531B1 Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds |
| 12/13/2006 | EP1272219B1 New combination of a betablocker and a cholesterol-lowering agent |
| 12/13/2006 | EP1268558B1 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 12/13/2006 | EP1261712B1 Proteins named fctrx and nucleic acids encoding same |
| 12/13/2006 | EP1248598B1 Osmotic device having a preformed passageway that increases in size |
| 12/13/2006 | EP1230922B1 Agents for promoting fattening of animals and method of promoting fattening |
| 12/13/2006 | EP1216042B1 Formulations of paclitaxel entrapped into nanoparticles of polymeric micelles |
| 12/13/2006 | EP1179067B1 Neuroprotective properties of gdf-15, a member of the tgf-beta superfamily |
| 12/13/2006 | EP1171156B1 Isolierte inslen, die insulin-produzierende zellen enthalten, beschichtete mit heparin |
| 12/13/2006 | EP1148880B1 Methods for restoring and/or enhancing accommodation in pseudo phakia |
| 12/13/2006 | EP1143896B1 Methods of hydrating the nasal mucosal surface |
| 12/13/2006 | EP1126872B1 CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT |
| 12/13/2006 | EP1123392B1 Prv-1 gene and the use thereof |
| 12/13/2006 | EP1100490B1 Short contact treatment of acne and photoaging with topical retinoids |
| 12/13/2006 | EP1093468B1 Polymers for delivering nitric oxide in vivo |
| 12/13/2006 | EP1091930B1 C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
| 12/13/2006 | EP1024836B1 Compositions for delivering genes to antigen presenting cells of the skin |
| 12/13/2006 | EP0927043B1 Compositions for gene transfer to the central nervous system |
| 12/13/2006 | EP0910359B1 Selection and/or enhancement of resident microorganisms in the gastrointestinal tract |
| 12/13/2006 | EP0883343B1 Compositions for treating ischemic tissue |
| 12/13/2006 | EP0854885B1 Recombinant anti-cd4 antibodies for human therapy |
| 12/13/2006 | EP0787002B1 Competitive progesterone antagonists for regulating female fertility as required |
| 12/13/2006 | EP0651805B1 Method of intracellular binding of target molecules |
| 12/13/2006 | CN1878820A Dispersions of sulfonic acid group-containing, unsaturated and amorphous polyesters based on defined dicidol isomers |
| 12/13/2006 | CN1878794A NGF antagonist and opioid analgesic use in pain treatment |
| 12/13/2006 | CN1878786A Novel 17beta-hydroxysteroid dehydrogenase type i inhibitors |
| 12/13/2006 | CN1878779A 2'oxo-voruscharin and derivatives thereof |
| 12/13/2006 | CN1878777A 2,3-dihydro-6-nitroimidazo (2,1-b) oxazole compounds for the treatment of tuberculosis |
| 12/13/2006 | CN1878776A Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases |
| 12/13/2006 | CN1878773A Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands |
| 12/13/2006 | CN1878772A Bicyclic pyrazolone cytokine inhibitors |
| 12/13/2006 | CN1878771A Substituted bicyclic quinazolin-4-ylamine derivatives |
| 12/13/2006 | CN1878769A 细胞因子抑制剂 Cytokine inhibitor |
| 12/13/2006 | CN1878768A Heteroaryl deravatives as PPAR activators |
| 12/13/2006 | CN1878767A Azole-based kinase inhibitors |
| 12/13/2006 | CN1878766A Methods for synthesizing quinolinone compounds |
| 12/13/2006 | CN1878765A Synthesis of quinoline 5-carboxamides useful for the preparation of PDE IV inhibitors |
| 12/13/2006 | CN1878764A Beta-lactams for treatment of cns disorders |
| 12/13/2006 | CN1878762A Morpholine derivatives as norepinephrine reuptake inhibitors |
| 12/13/2006 | CN1878760A Crystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s)-3, 5-dihydroxyhept-6-enoicacid] calcium salt |
| 12/13/2006 | CN1878758A Crf antagonists and heterobicyclic compounds |
| 12/13/2006 | CN1878757A The derivatives of pyridone and use thereof |
| 12/13/2006 | CN1878756A Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands |
| 12/13/2006 | CN1878755A Pentafluorosulfanylbenzoylguanidines, process for their preparation, use as a medicament or diagnostic aid, and medicament comprising same |
| 12/13/2006 | CN1878748A Process of hydrocyanation of unsaturated carboxylic acid derivatives |
| 12/13/2006 | CN1878602A Manufacturing method of organic compound particulate |
| 12/13/2006 | CN1878569A Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| 12/13/2006 | CN1878559A Desensitization of compliment activation using monocyte/macrophage inhibitory compounds |
| 12/13/2006 | CN1878558A Graduated estrogen contraceptive |
| 12/13/2006 | CN1878557A Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients |
| 12/13/2006 | CN1878556A Combinations of drugs for the treatment of neoplasms |
| 12/13/2006 | CN1878555A Combination comprising n-(3-methoxy-5-methylpyrazin-2yl)-2-(4-[1,3,4-oxadiazol-2-y1]pyridine-3-sulphonamide and an lhrh analogue and/or bisphosphonate |
| 12/13/2006 | CN1878554A 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses |
| 12/13/2006 | CN1878553A High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins |
| 12/13/2006 | CN1878552A Methods of use of thrombin receptor antagonists |
| 12/13/2006 | CN1878551A 4-phenyl piperdine sulfonyl glycine transporter inhibitors |
| 12/13/2006 | CN1878550A Methods for identifying improved, non-sedating alpha-2 agonists |
| 12/13/2006 | CN1878549A Percutaneous absorption type cerebral protective agent |
| 12/13/2006 | CN1878548A Combinations of at1-antagonists, amiloride or triamterine, and a diuretic. |
| 12/13/2006 | CN1878547A Synthesis of oligomeric epicatechin and catechin-derived procyanidins |
| 12/13/2006 | CN1878546A Combination comprising an alpha-2-delta ligand and an SSRI and/or SNRI for treatment of depression and anxiety disorders |
| 12/13/2006 | CN1878545A Thyroid hormone analogs and methods of use |
| 12/13/2006 | CN1878544A Use of enos transcription enhancers in the cell therapy of ischemic heart diseases |
| 12/13/2006 | CN1878538A Solid amorphous dispersions of an MTP inhibitor for treatment of obesity |
| 12/13/2006 | CN1878536A Antimicrobial compositions and methods |
| 12/13/2006 | CN1878529A Combined cosmetic or therapeutic preparation |
| 12/13/2006 | CN1878464A Therapeutic delivery of carbon monoxide |
| 12/13/2006 | CN1876796A Vigorous wine and preparation method thereof |
| 12/13/2006 | CN1876683A Human antibodies that bind human TNFalpha |
| 12/13/2006 | CN1876679A Compounds from moraxella catarrhalis |
| 12/13/2006 | CN1876672A Steroid imidazole salt compound and its preparing process |
| 12/13/2006 | CN1876665A Method for refining oxaliplatin |
| 12/13/2006 | CN1876658A Gambogicacid derivative and its preparation method and uses in pharmacy |